Related Experiment Video

Updated: Aug 15, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol

Steven A Grover1, Marc Dorais, Louis Coupal

  • 1Centre for the Analysis of Cost-Effective Care, The Montreal General Hospital, Quebec, Canada. steven.grover@mcgill.ca

Epidemiology (Cambridge, Mass.)
|July 16, 2003
PubMed

Insights

The ratio of low-density lipoprotein (LDL) to high-density lipoprotein (HDL) cholesterol may not fully predict coronary risk. Analyzing the interaction between LDL and HDL levels offers a more accurate assessment of cardiovascular event risk.

Area of Science:

  • Cardiovascular disease research
  • Lipid metabolism and cardiovascular health

Background:

  • Current guidelines advocate using cholesterol ratios to estimate coronary risk.
  • The ratio of total cholesterol to HDL or LDL to HDL is commonly used.

Purpose of the Study:

  • To analyze the relationship between LDL and HDL cholesterol levels in predicting future coronary events.
  • To compare the predictive power of the LDL/HDL ratio against the independent effects and interaction of LDL and HDL.

Main Methods:

  • Utilized data from the Lipid Research Clinics Follow-up Cohort (4684 participants, ~12 years follow-up).
  • Developed multivariate equations to predict coronary deaths.
  • Compared predictive models including LDL/HDL ratio, independent LDL/HDL effects, and LDL-HDL interaction term.
  • Forecasted 10-year coronary death risk based on lipid levels and conventional risk factors.

Main Results:

  • LDL and HDL levels, along with their interaction, are independent risk factors for coronary death.
  • Benefits of HDL increase are most significant in individuals with high LDL.
  • Benefits of LDL decrease are greatest in individuals with low HDL.
  • Models incorporating LDL-HDL interaction provided more accurate treatment benefit predictions.

Conclusions:

  • The LDL/HDL ratio alone may not fully represent the complex interplay between LDL and HDL.
  • A comprehensive assessment considering the interaction of LDL and HDL is crucial for accurate coronary risk prediction.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...